Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 18 | 2024 | 230 | 4.920 |
Why?
|
| Chromatography, High Pressure Liquid | 17 | 2024 | 458 | 2.360 |
Why?
|
| Ovarian Neoplasms | 13 | 2015 | 406 | 1.460 |
Why?
|
| Chromatography, Liquid | 11 | 2023 | 173 | 1.450 |
Why?
|
| Rats | 26 | 2024 | 3701 | 1.240 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2021 | 1737 | 1.080 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2021 | 860 | 1.060 |
Why?
|
| Drug Monitoring | 2 | 2025 | 20 | 0.970 |
Why?
|
| Microsomes, Liver | 2 | 2024 | 71 | 0.950 |
Why?
|
| Nicotinic Acids | 3 | 2013 | 10 | 0.940 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 1058 | 0.900 |
Why?
|
| Animals | 34 | 2025 | 16695 | 0.870 |
Why?
|
| Solvents | 2 | 2015 | 109 | 0.850 |
Why?
|
| Anti-Retroviral Agents | 1 | 2025 | 158 | 0.850 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2015 | 727 | 0.830 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 222 | 0.790 |
Why?
|
| Biological Availability | 6 | 2021 | 115 | 0.760 |
Why?
|
| Health Personnel | 1 | 2025 | 262 | 0.760 |
Why?
|
| Pyridazines | 2 | 2013 | 16 | 0.740 |
Why?
|
| Propolis | 1 | 2021 | 6 | 0.720 |
Why?
|
| Glucuronides | 5 | 2025 | 23 | 0.710 |
Why?
|
| Weightlessness | 1 | 2021 | 27 | 0.680 |
Why?
|
| Flavonoids | 1 | 2021 | 94 | 0.680 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2015 | 57 | 0.660 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 67 | 0.650 |
Why?
|
| Stilbenes | 2 | 2021 | 44 | 0.630 |
Why?
|
| Mycophenolic Acid | 3 | 2025 | 17 | 0.580 |
Why?
|
| Mannose | 3 | 2017 | 30 | 0.580 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 415 | 0.530 |
Why?
|
| Serum | 1 | 2016 | 17 | 0.520 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 979 | 0.480 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 56 | 0.480 |
Why?
|
| Proline | 2 | 2015 | 39 | 0.470 |
Why?
|
| Solubility | 4 | 2021 | 134 | 0.450 |
Why?
|
| Indoles | 1 | 2016 | 178 | 0.450 |
Why?
|
| Male | 23 | 2025 | 22779 | 0.450 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 10 | 0.420 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 49 | 0.410 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 134 | 0.410 |
Why?
|
| Drug Stability | 5 | 2018 | 127 | 0.410 |
Why?
|
| Administration, Oral | 3 | 2021 | 256 | 0.400 |
Why?
|
| Blood Coagulation | 1 | 2013 | 29 | 0.400 |
Why?
|
| Ovary | 1 | 2013 | 112 | 0.400 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 137 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 147 | 0.390 |
Why?
|
| Warfarin | 1 | 2013 | 66 | 0.380 |
Why?
|
| Humans | 33 | 2025 | 42163 | 0.380 |
Why?
|
| Antipyrine | 1 | 2012 | 4 | 0.370 |
Why?
|
| Curcumin | 1 | 2013 | 115 | 0.370 |
Why?
|
| Hindlimb Suspension | 1 | 2012 | 16 | 0.370 |
Why?
|
| Anticoagulants | 1 | 2013 | 121 | 0.370 |
Why?
|
| Menthol | 1 | 2012 | 23 | 0.370 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 54 | 0.360 |
Why?
|
| Microsomes | 2 | 2022 | 55 | 0.360 |
Why?
|
| HIV Infections | 1 | 2025 | 2535 | 0.340 |
Why?
|
| Neoplasms | 2 | 2022 | 1341 | 0.330 |
Why?
|
| Species Specificity | 2 | 2024 | 279 | 0.320 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2015 | 93 | 0.320 |
Why?
|
| Female | 25 | 2025 | 24018 | 0.310 |
Why?
|
| Methylcellulose | 1 | 2009 | 7 | 0.310 |
Why?
|
| Half-Life | 3 | 2015 | 63 | 0.310 |
Why?
|
| Isoxazoles | 1 | 2009 | 14 | 0.310 |
Why?
|
| Sucrose | 1 | 2009 | 33 | 0.310 |
Why?
|
| Anticonvulsants | 1 | 2009 | 39 | 0.310 |
Why?
|
| Nicotine | 1 | 2012 | 290 | 0.300 |
Why?
|
| Drug Compounding | 1 | 2009 | 90 | 0.290 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 27 | 0.290 |
Why?
|
| Nanoparticles | 3 | 2022 | 449 | 0.280 |
Why?
|
| Vitamin A | 1 | 2008 | 85 | 0.280 |
Why?
|
| Delayed-Action Preparations | 2 | 2013 | 72 | 0.270 |
Why?
|
| Vitamins | 1 | 2008 | 81 | 0.270 |
Why?
|
| Genetic Variation | 3 | 2015 | 429 | 0.270 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 84 | 0.270 |
Why?
|
| Risk | 5 | 2015 | 289 | 0.260 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 4 | 0.260 |
Why?
|
| Middle Aged | 10 | 2025 | 11819 | 0.260 |
Why?
|
| Niacin | 1 | 2006 | 23 | 0.260 |
Why?
|
| Genome-Wide Association Study | 4 | 2015 | 421 | 0.240 |
Why?
|
| Linear Models | 4 | 2021 | 311 | 0.230 |
Why?
|
| Diclofenac | 1 | 2024 | 5 | 0.230 |
Why?
|
| Plasma | 2 | 2022 | 38 | 0.230 |
Why?
|
| Texas | 2 | 2025 | 428 | 0.230 |
Why?
|
| Mice | 9 | 2024 | 6490 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2010 | 501 | 0.220 |
Why?
|
| Glycosides | 1 | 2024 | 22 | 0.220 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 94 | 0.220 |
Why?
|
| Nanospheres | 2 | 2014 | 7 | 0.220 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 602 | 0.210 |
Why?
|
| Alleles | 3 | 2021 | 352 | 0.210 |
Why?
|
| Phenols | 1 | 2024 | 102 | 0.200 |
Why?
|
| Biological Transport | 2 | 2021 | 201 | 0.190 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 77 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2015 | 587 | 0.190 |
Why?
|
| Glucuronidase | 1 | 2022 | 21 | 0.190 |
Why?
|
| Time Factors | 3 | 2012 | 1848 | 0.190 |
Why?
|
| Genotype | 6 | 2015 | 796 | 0.190 |
Why?
|
| Adult | 8 | 2025 | 13458 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 21 | 0.180 |
Why?
|
| Fenoldopam | 1 | 2021 | 3 | 0.180 |
Why?
|
| Nitriles | 2 | 2013 | 78 | 0.180 |
Why?
|
| Honey | 1 | 2021 | 15 | 0.180 |
Why?
|
| Magnesium Hydroxide | 1 | 2021 | 2 | 0.180 |
Why?
|
| Antacids | 1 | 2021 | 3 | 0.180 |
Why?
|
| Antidiarrheals | 1 | 2021 | 4 | 0.180 |
Why?
|
| Bismuth | 1 | 2021 | 5 | 0.180 |
Why?
|
| Aluminum Hydroxide | 1 | 2021 | 8 | 0.170 |
Why?
|
| Salicylates | 1 | 2021 | 9 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 30 | 0.170 |
Why?
|
| Weightlessness Simulation | 1 | 2021 | 26 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1266 | 0.170 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 118 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2013 | 130 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2021 | 102 | 0.170 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 72 | 0.170 |
Why?
|
| Drug Interactions | 1 | 2021 | 151 | 0.170 |
Why?
|
| Gene Frequency | 1 | 2021 | 203 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2025 | 475 | 0.170 |
Why?
|
| Risk Factors | 6 | 2015 | 3942 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.170 |
Why?
|
| Oxyquinoline | 1 | 2020 | 6 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2021 | 83 | 0.160 |
Why?
|
| Tongue | 1 | 2019 | 14 | 0.160 |
Why?
|
| Aged | 7 | 2017 | 7982 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 47 | 0.160 |
Why?
|
| Liver | 3 | 2024 | 503 | 0.150 |
Why?
|
| Tissue Distribution | 4 | 2023 | 230 | 0.150 |
Why?
|
| Pharmaceutical Solutions | 2 | 2015 | 5 | 0.150 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 4 | 0.150 |
Why?
|
| Quantitative Trait Loci | 2 | 2015 | 88 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 457 | 0.140 |
Why?
|
| Kinetics | 2 | 2024 | 698 | 0.140 |
Why?
|
| Protein Binding | 3 | 2015 | 1076 | 0.130 |
Why?
|
| Temperature | 2 | 2009 | 314 | 0.130 |
Why?
|
| Rats, Inbred F344 | 3 | 2021 | 256 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2017 | 70 | 0.130 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 101 | 0.120 |
Why?
|
| Adenoma | 1 | 2017 | 94 | 0.120 |
Why?
|
| Molecular Structure | 3 | 2024 | 560 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2014 | 95 | 0.120 |
Why?
|
| Copper Radioisotopes | 1 | 2015 | 9 | 0.120 |
Why?
|
| Phototherapy | 1 | 2015 | 25 | 0.120 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 2 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 44 | 0.120 |
Why?
|
| Lutetium | 1 | 2015 | 3 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 92 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2015 | 17 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 62 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2015 | 75 | 0.110 |
Why?
|
| Gonadotropins | 1 | 2014 | 27 | 0.110 |
Why?
|
| Anilides | 1 | 2014 | 28 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 55 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 93 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 50 | 0.110 |
Why?
|
| Bilirubin | 1 | 2014 | 19 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 58 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 69 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 385 | 0.110 |
Why?
|
| Itraconazole | 1 | 2013 | 13 | 0.110 |
Why?
|
| Endometriosis | 1 | 2015 | 81 | 0.110 |
Why?
|
| Polysorbates | 1 | 2013 | 10 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 21 | 0.110 |
Why?
|
| Antibodies | 1 | 2014 | 140 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 36 | 0.100 |
Why?
|
| Polyglycolic Acid | 1 | 2013 | 48 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2598 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 228 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 81 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1586 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 2 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 318 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2013 | 28 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 10 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2013 | 110 | 0.100 |
Why?
|
| Biotransformation | 1 | 2013 | 68 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2013 | 98 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 362 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 933 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 287 | 0.100 |
Why?
|
| Reference Standards | 2 | 2013 | 55 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2013 | 189 | 0.100 |
Why?
|
| Gold | 1 | 2014 | 153 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2013 | 169 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 206 | 0.090 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 70 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 169 | 0.090 |
Why?
|
| Cotinine | 1 | 2012 | 44 | 0.090 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 92 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 845 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 502 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 149 | 0.090 |
Why?
|
| Ethanol | 1 | 2013 | 221 | 0.090 |
Why?
|
| Metabolomics | 3 | 2017 | 90 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 10 | 0.090 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2010 | 14 | 0.090 |
Why?
|
| Lymphokines | 1 | 2010 | 17 | 0.090 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 14 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 30 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 227 | 0.080 |
Why?
|
| Haplotypes | 1 | 2010 | 197 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 428 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 274 | 0.080 |
Why?
|
| Kidney | 2 | 2024 | 363 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 140 | 0.080 |
Why?
|
| Refrigeration | 1 | 2009 | 4 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 526 | 0.080 |
Why?
|
| Drug Storage | 1 | 2009 | 28 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 479 | 0.080 |
Why?
|
| Suspensions | 1 | 2009 | 48 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1554 | 0.070 |
Why?
|
| Binding Sites | 1 | 2010 | 670 | 0.070 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 19 | 0.070 |
Why?
|
| Sex Factors | 1 | 2012 | 1008 | 0.070 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 103 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1019 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1804 | 0.060 |
Why?
|
| Monosaccharides | 1 | 2024 | 13 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2008 | 461 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 201 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2803 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1679 | 0.050 |
Why?
|
| Methanol | 1 | 2023 | 21 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 686 | 0.050 |
Why?
|
| Sulfides | 1 | 2023 | 77 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2015 | 403 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 205 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1001 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 95 | 0.050 |
Why?
|
| Glucuronates | 1 | 2021 | 8 | 0.050 |
Why?
|
| Liposomes | 1 | 2022 | 130 | 0.040 |
Why?
|
| Sulfates | 1 | 2021 | 26 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2021 | 29 | 0.040 |
Why?
|
| Intestines | 1 | 2021 | 71 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 80 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 82 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 126 | 0.040 |
Why?
|
| Hydrazones | 1 | 2020 | 11 | 0.040 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 50 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 64 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 273 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 279 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 226 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 181 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Hypoxanthine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 4 | 0.030 |
Why?
|
| Xanthine | 1 | 2017 | 4 | 0.030 |
Why?
|
| Caffeine | 1 | 2017 | 28 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 44 | 0.030 |
Why?
|
| Nuchal Cord | 1 | 2015 | 2 | 0.030 |
Why?
|
| United States | 1 | 2006 | 5072 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.030 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 62 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 97 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 11 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2014 | 2111 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 107 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 84 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 148 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 661 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 174 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 144 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 158 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 16 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 146 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 310 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 129 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 39 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 65 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2013 | 29 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 52 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 339 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 330 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 387 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 246 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 187 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 850 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2014 | 176 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 722 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 534 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1729 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 1169 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2013 | 393 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 683 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2485 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4936 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 5950 | 0.010 |
Why?
|